υa	te: <u>Jan. 25°, 2022</u>			
	ur Name: <u>Bolun Zhou</u>			
Ma	anuscript Title: <u>A ne</u>	w N descriptor for non-sm	all cell lung cancer: the classification based on anatom	<u>ic</u>
loc	ation, number and ratio of i	metastatic lymph nodes		
Ma	anuscript number (if known)	: <u>TLCR-21-933</u>		
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" means affected by the content on the cossarily indicate a bias. It is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the <u>current</u>	
ma	nuscript only.			
to me	the epidemiology of hyperto edication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensi the manuscript. d in this manuscript without time limit. For all other it	ve
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	·	
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
No time limit for this item.				
		Time frame: past	36 months	
2	Grants or contracts from	X None		
_	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	X None		

Consulting fees

\_X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V. None	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing hox:
	None.		
Dla	ase place an "Y" nevt to the	following statement to it	odicato vour agrooment

Da	te: <u>Jan. 25<sup>th</sup>, 2022</u>			
Yo	ur Name: <u>Ruochuan Za</u>	ang		
Ma	nuscript Title: <u>A ne</u>	w N descriptor for non-sr	mall cell lung cancer: the classification based on anatomic	
loc	ation, number and ratio of	metastatic lymph nodes		
Ma	nuscript number (if known)	): <u>TLCR-21-933</u>		
rel par to	ated to the content of your rties whose interests may b	manuscript. "Related" mo e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a	
The			nips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.	i
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other item	s,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	st 36 months	
3	Royalties or licenses	X None		

Consulting fees

\_X\_\_None

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony	X140116	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>3</b> ,		
8	Patents planned, issued or	X None	
J	pending		
	1		
0	Dauticination are Date	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
_			
	None.		
L			
Ple	ease place an "X" next to the	e following statement to i	ndicate your agreement:

Date: Jan. 25 <sup>t</sup>	1, 2022
Your Name:	Moyan Zhang
<b>Manuscript Title:</b>	A new N descriptor for non-small cell lung cancer: the classification based on anatomic
location, number	and ratio of metastatic lymph nodes
Manuscript numb	er (if known): TLCR-21-933
related to the con	transparency, we ask you to disclose all relationships/activities/interests listed below that are tent of your manuscript. "Related" means any relation with for-profit or not-for-profit third
parties whose int	erests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
5	pending	^	
	penung		+
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
-	materials, drugs, medical writing, gifts or other		
	services		
4.2		V N	
13	Other financial or non-	XNone	
	financial interests		
Ple	ase summarize the above c	onflict of interest in the f	ollowing box:
	None.		
	ase place an "Y" next to the	following statement to	

Date: <u>Jan. 25<sup>th</sup></u>	, 2022
Your Name:	
Manuscript Title:	A new N descriptor for non-small cell lung cancer: the classification based on anatomic
location, number	and ratio of metastatic lymph nodes
Manuscript numb	er (if known): TLCR-21-933
related to the con	transparency, we ask you to disclose all relationships/activities/interests listed below that are tent of your manuscript. "Related" means any relation with for-profit or not-for-profit third erests may be affected by the content of the manuscript. Disclosure represents a commitment
	nd does not necessarily indicate a hias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
5	pending	^	
	penung		+
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
-	materials, drugs, medical writing, gifts or other		
	services		
4.2		V N	
13	Other financial or non-	XNone	
	financial interests		
Ple	ase summarize the above c	onflict of interest in the f	ollowing box:
	None.		
	ase place an "Y" next to the	following statement to	

ICIVIJE I	DISCLUSURE FURIVI
Date:Jan. 25 <sup>th</sup> , 2022	
Your Name: <u>Lei Liu</u>	
Manuscript Title: A new N descriptor for nor	n-small cell lung cancer: the classification based on anatomic
location, number and ratio of metastatic lymph nod	es
Manuscript number (if known): TLCR-21-93	33
related to the content of your manuscript. "Related"	
The following questions apply to the author's relation manuscript only.	onships/activities/interests as they relate to the <u>current</u>
- · · · · · · · · · · · · · · · · · · ·	d be <u>defined broadly</u> . For example, if your manuscript pertains clare all relationships with manufacturers of antihypertensive d in the manuscript.
In item #1 below, report all support for the work rep the time frame for disclosure is the past 36 months.	ported in this manuscript without time limit. For all other items,
Name all entities with	Specifications/Comments

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	X None	

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
0	Detents planned issued an	V. None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
-	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^NOTIC	
4.2		V N	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	Nana		
	None.		
Dla	ase place an "Y" peyt to the	following statement to	indicate your agreement:

Da	ite: <u>Jan. 25<sup>th</sup>, 2022</u>					
Yo	ur Name: Fenglong Bie					
Ma	anuscript Title: A ne	w N descriptor for non-sr	mall cell lung cancer: the classification based on anatomic			
loc	cation, number and ratio of	metastatic lymph nodes				
Ma	anuscript number (if known)	): <u>TLCR-21-933</u>				
	-		Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third			
-	<del>-</del>	<del>-</del>	of the manuscript. Disclosure represents a commitment			
	transparency and does not ationship/activity/interest,	=	s. If you are in doubt about whether to list a lo so.			
	e following questions apply anuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>			
to	• •	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.			
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other items	i,		
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initi	al planning of the work			
1	All support for the present	XNone				
	manuscript (e.g., funding,					
	provision of study materials,					
medical writing, article processing charges, etc.)						
						No time limit for this item.
		Time frame: pas	st 36 months			
)	Grants or contracts from	X None	To months			
<u>-</u>	any entity (if not indicated	^NOTIE				
	in item #1 above).					

Royalties or licenses

Consulting fees

X\_\_None

\_X\_\_None

3

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
0	Detents planned issued an	V. None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
-	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^NOTIC	
4.2		V N	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	Nana		
	None.		
Dla	ase place an "Y" peyt to the	following statement to	indicate your agreement:

Da	te: <u>Jan. 25<sup>th</sup>, 2022</u>		
Yo	ur Name: Yue Peng		
Ma	anuscript Title: <u>A ne</u>	w N descriptor for non-sm	nall cell lung cancer: the classification based on anatomic
	ation, number and ratio of		
Ma	anuscript number (if known)	): <u>TLCR-21-933</u>	
rel par to rel The ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act	manuscript. "Related" mee affected by the content of necessarily indicate a bias it is preferable that you do to the author's relationsh ivities/interests should be ension, you should declare	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
me In i	edication, even if that medic item #1 below, report all su e time frame for disclosure i	pport for the work reporte	the manuscript.  ed in this manuscript without time limit. For all other items
me In i	item #1 below, report all su	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
me In i	item #1 below, report all su	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
me In i	item #1 below, report all su	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
mee In i the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial XNone	Specifications/Comments (e.g., if payments were made to you or to your institution)
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
mee In i the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	pport for the work reporters the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial XNone	Specifications/Comments (e.g., if payments were made to you or to your institution)

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	ase summarize the above co	onflict of interest in the fo	llowing box:
Dla	ase place an "Y" nevt to the	following statement to it	odicato vour agraement

Da	te: <u>Jan. 25<sup>th</sup>, 2022</u>			
Yo	ur Name: <u>Guangyu Bai</u>			
Ma	nuscript Title: <u>A ne</u>	w N descriptor for non-sr	mall cell lung cancer: the classification based on anatomic	
loc	ation, number and ratio of	metastatic lymph nodes		
Ma	anuscript number (if known	): <u>TLCR-21-933</u>		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.	
	e following questions apply	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertedication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
	All according to the constant	1		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		

Time frame: past 36 months

X\_\_None

X\_\_None

X\_\_None

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

2

3

4

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	ase summarize the above co	onflict of interest in the fo	llowing box:
Dla	ase place an "Y" nevt to the	following statement to it	odicato vour agraement

Da	te: <u>Jan. 25<sup>th</sup>, 2022</u>			
Yo	ur Name: Shugeng Ga	0		
Ma	anuscript Title: <u>A ne</u>	w N descriptor for non-sm	all cell lung cancer: the classification based on anatomic	<u>c</u>
loc	ation, number and ratio of	metastatic lymph nodes		
Ma	anuscript number (if known	): <u>TLCR-21-933</u>		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply anuscript only.	to the author's relationsh	ps/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure		ed in this manuscript without time limit. For all other ite	∍ms,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			

Time frame: past 36 months

\_X\_\_None

X\_\_None

X\_\_None

provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** 

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

2

3

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	ase summarize the above co	onflict of interest in the fo	llowing box:
Dla	ase place an "Y" nevt to the	following statement to it	odicato vour agraement